Results 91 to 100 of about 3,123 (163)

Modeled Dalbavancin Transmembrane Clearance during Intermittent and Continuous Renal Replacement Therapies

, 2010
<i>Background/Aims:</i> Knowledge of dalbavancin renal replacement therapy (RRT) disposition is vital to ensure appropriate dosing. In vitro models of continuous RRT and intermittent hemodialysis (IHD) were used to determine dalbavancin ...
A. Mary Vilay, Bruce A. Mueller, Jignesh H. Patel, Krishna H. Shah, Mariann D. Churchwell, Daryl D. DePestel   +5 more
core   +1 more source

Successful treatment of Enterococcus faecalis bacteremia with dalbavancin as an outpatient in an intravenous drug user

International Journal of Infectious Diseases, 2018
This report describes the treatment of a 35-year-old male who presented to the emergency department with an empyema, and who had a long hospital course complicated by a catheter-related bloodstream infection and a history of intravenous drug use.
Bruce M. Jones, Chelsea Keedy, Melissa Wynn   +2 more
doaj   +1 more source

Real-life experience with IV dalbavancin in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry

Journal of Global Antimicrobial Resistance
: Objectives: We report the use of IV dalbavancin in Canadian patients using data captured by the national CLEAR registry. Methods: The CLEAR registry uses the web-based data management program, REDCap™ (online survey https://rcsurvey.radyfhs.umanitoba ...
George Zhanel, Michael Silverman, Janhavi Malhotra, Melanie Baxter, Reza Rahimi, Neal Irfan, Gabriel Girouard, Rita Dhami, Melissa Kucey, Vida Stankus, Kristin Schmidt, Sébastien Poulin, William Connors, Carlo Tascini, Andrew Walkty, James Karlowsky   +15 more
doaj   +1 more source

The role of dalbavancin in skin and soft tissue infections.

, 2018
Purpose of review The increase of skin and soft tissue infections (SSTIs) represents a major concern both in community and in the hospital setting.
Bassetti M, Righi E., Carnelutti A., Bassetti M., Peghin M, Peghin M., Righi E, Carnelutti A   +7 more
core   +1 more source

Fever for days: A challenging case of dalbavancin-induced fever

Dalbavancin is a novel long acting lipoglycopeptide antibiotic with a favorable safety profile approved for treating Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by Gram-positive organisms.
Benjamin Albrecht, Ahmed Babiker, Claire Wan, Sarah Green, Mohamed A. Almahal   +4 more
core   +1 more source

Clinical, organizational, and pharmacoeconomic perspectives of dalbavancin vs standard of care in the infectious disease network

Global & Regional Health Technology Assessment
Introduction: The therapeutic approach to the patient with acute bacterial skin and skin structure infection (ABSSSI) and complicated infections often involves the early transition from intravenous to oral therapy (early switch) or early discharge.
Daniela Segala, Marco Barbieri, Mariachiara Di Nuzzo, Melissa Benazzi, Aurora Bonazza, Letizia Romanini, Brunella Quarta, Kristian Scolz, Anna Marra, Diana Campioni, Rosario Cultrera   +10 more
doaj   +1 more source

Dalbavancin: a novel lipoglycopeptide antibacterial

, 2006
Dalbavancin is a new lipoglycopeptide antibacterial possessing in vitro activity against a variety of gram-positive pathogens. Against methicillin-susceptible and methicillin-resistant Staphylococcus aureus, it has demonstrated favorable minimum ...
Roecker, Andrew M., Pope, Scott D.
core   +1 more source

Addressing catheter lock therapy: Does heparin reduce the bioactivity of dalbavancin when together in solution during freezing?

M. Guembe is supported by the Miguel Servet Program (ISCIII-MICINN, MS18/00008) of the Health Research Fund (FIS) of the Carlos III Health Institute (ISCIII), Madrid, Spain. M. Díaz-Navarro is supported by ISCIII (FI22/00022).
Hafian, Rama, Pérez Granda, María Jesús, Cercenado Mansilla, Emilia, Muñoz García, Patricia Carmen, Díaz Navarro, Marta, Guembe, María   +5 more
core   +1 more source

Dalbavancin-resistant Staphylococcus epidermidis in vivo selection following a prosthetic joint infection: phenotypic and genomic characterization

International audienceBackground Dalbavancin is a lipoglycopeptide antibiotic with a wide spectrum of activity against Gram-positive bacteria, including MDR isolates.
Fayoux, E, Barbier, P, Lecomte, R, Guillouzouic, A, Bémer, P, Ruffier D’epenoux, L, Nich, C, Grégoire, M, Deschanvres, C, Corvec, S   +9 more
core   +1 more source

Effects of Sub-Inhibitory Rifampicin, Minocycline, and Dalbavancin on Early Biofilm Formation and Transcriptional Responses in <i>Staphylococcus aureus</i> SA113. [PDF]

Microorganisms
Bieda A, Illner S, Senz V, Oschatz S, Grabow N, Löbermann M, Reisinger EC, Sombetzki M.   +7 more
europepmc   +1 more source